Nonspecific secretory immunity in HIV-infected patients with oral candidiasis

Journal of Acquired Immune Deficiency Syndromes

Volumn 31, Issue 3, 2002, Pages 276-284

  Bard, E ^a   Laibe, S ^a,b   Clair, S ^a,b   Biichle S ^a   Millon, L ^a,b   Drobacheff, C ^a,b   Bettinger, D ^a   Seilles E ^a   Meillet, D ^a,b  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b Hôpital Intercommunal Sud Léman Valserine   (France)

Author keywords

HIV; Innate and mucosal immunity; Lactoferrin; Lysozyme; Oral candidiasis; Secretory IgA.

Indexed keywords

IMMUNOGLOBULIN A; LACTOFERRIN; LYSOZYME;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; FLUOROMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUCOSAL IMMUNITY; NEUTROPHIL; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SALIVA LEVEL; THRUSH;

EID: 0036841590     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200211010-00002     Document Type: Article

References (49)

1. McGhee JR, Mestecky J, Elson CO, et al. Regulation of IgA synthesis and immune response by T cells and interleukins. J Clin Immunol 1989;9:175-99.
2. Medzhitov R, Janeway C. Innate immunity. N Engl J Med 2000;343:338-44.
3. Stokes CR, Soothill JF, Turner MW. Immune exclusion is a function of IgA. Nature 1975;255:745-6.
4. Goldblum RM. The role of IgA in local immune protection. J Clin Immunol 1990;10:64S-70S; discussion 70S-1S.
5. Mazanec MB, Nedrud JG, Kaetzel CS, et al. A three-tiered view of the role of IgA in mucosal defense. Immunol Today 1993;14:430-5.
6. Johansen FE, Braathen R, Brandtzaeg P. Role of J chain in secretory immunoglobulin formation. Scand J Immunol 2000;52:240-8.
7. Brandtzaeg P, Berstad AE, Farstad IN, et al. Mucosal immunity - A major adaptive defense mechanism. Behring Inst Mitt 1997:1-23.
8. Wu T, Samaranayake LP, Leung WK, et al. Inhibition of growth and secreted aspartyl proteinase production in Candida albicans by lysozyme. J Med Microbiol 1999;48:721-30.
9. Mandel ID, Barr CE, Turgeon L. Longitudinal study of parotid saliva in HIV-1 infection. J Oral Pathol Med 1992;21:209-13.
10. Pruitt KM, Rahemtulla B, Rahemtulla F, et al. Innate tumoral factors. In: Ogra PL, Mestecky J, Lamm ME, et al., eds. Handbook of Mucosal Immunology. Vol. 1. San Diego: Academic Press, 1999:65-88.
11. Marquis G, Montplaisir S, Garzon S, et al. Fungitoxicity of muramidase. Ultrastructural damage to Candida albicans. Lab Invest 1982;46:627-36.
12. Samaranayake YH, MacFarlane TW, Aitchison TC, et al. The in vitro lysozyme susceptibility of Candida albicans cultured in carbohydrate-supplemented media. Oral Microbiol Immunol 1993;8:177-81.
13. Levay PF, Viljoen M. Lactoferrin: A general review. Hematologica 1995;80:252-67.
14. van der Strate BW, Harmsen MC, The TH, et al. Plasma lactoferrin levels are decreased in end-stage AIDS patients. Viral Immunol 1999;12:197-203.
15. Kanyshkova TG, Buneva VN, Nevinsky GA. Lactoferrin and its biologic functions. Biochemistry (Mosc) 2001;66:1-7.
16. Swart PJ, Kuipers ME, Smit C, et al. Antiviral effects of milk proteins: Acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro. AIDS Res Hum Retroviruses 1996;12:769-75.
17. Marchetti M, Longhi C, Conte MP, et al. Lactoferrin inhibits Herpes simplex virus type 1 adsorption to Vero cells. Antiviral Res 1996;29:221-31.
18. Harmsen MC, Swart PJ, de Bethune MP, et al. Antiviral effects of plasma and milk proteins: Lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 1995;172:380-8.
19. Muller F, Holberg-Petersen M, Rollag H, et al. Nonspecific oral immunity in individuals with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1992;5:46-51.
20. Benhamou Y, Kapel N, Hoang C, et al. Inefficacy of intestinal secretory immune response to Cryptosporidium in acquired immunodeficiency syndrome. Gastroenterology 1995;108:627-35.
21. Bard E, Laibe S, Riethmuller D, et al. Mucosal lysozyme lactoferrin and secretory IgA modifications in HIV and HBV infections [abstract]. Mucosal Immunology Update 2002;10(2,3).
22. Bard E, Riethmuller D, Biichle S, et al. Validation of high sensitive immunoenzymatic assay to establish the origin of immunoglobulins in female genital secretions. J Immunoassay 2002;23:145-162.
23. Delacroix DL. The Human Immunoglobulin: A System, its Vascular Compartment. Vol. 1. Louvain, Belgium: Catholic University, 1985.
24. Kapel N, Meillet D, Favennec L, et al. Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn's disease and ulcerative colitis. Eur J Clin Chem Clin Biochem 1992;30:197-202.
25. Jonard PP, Rambaud JC, Dive C, et al. Secretion of immunoglobulins and plasma proteins from the jejunal mucosa. Transport rate and origin of polymeric immunoglobulin A. J Clin Invest 1984;74:525-35.
26. Yeh CK, Dodds MW, Zuo P, et al. A population-based study of salivary lysozyme concentrations and candidal counts. Arch Oral Biol 1997;42:25-31.
27. Xu YY, Samaranayake YH, Samaranayake LP, et al. In vitro susceptibility of Candida species to lactoferrin. Med Mycol 1999;37:35-41.
28. Kuipers ME, de Vries HG, Eikelboom MC, et al. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob Agents Chemother 1999;43:2635-41.
29. Tenovuo J, Lumikari M, Soukka T. Salivary lysozyme, lactoferrin and peroxidases: Antibacterial effects on cariogenic bacteria and clinical applications in preventive dentistry. Proc Finn Dent Soc 1991;87:197-208.
30. Millon L, Drobacheff C, Piarroux R, et al. Longitudinal study of anti-Candida albicans mucosal immunity against aspartic proteinases in HIV-infected patients. J Acquir Immune Defic Syndr 2001;26:137-44.
31. Steinrauf LK, Shiuan D, Yang WJ, et al. Lysozyme association with nucleic acids. Biochem Biophys Res Commun 1999;266:366-70.
32. Defer MC, Dugas B, Picard O, et al. Impairment of circulating lactoferrin in HIV-1 infection. Cell Mol Biol (Noisy-le-grand) 1995;41:417-21.
33. Servais J, Nkoghe D, Schmit JC, et al. HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;28:221-5.
34. Okutomi T, Abe S, Tansho S, et al. Augmented inhibition of growth of Candida albicans by neutrophils in the presence of lactoferrin. FEMS Immunol Med Microbiol 1997;18:105-12.
35. Leigh JE, Steele C, Wormley FL Jr, et al. Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: A pilot study in HIV-positive individuals with oropharyngeal candidiasis. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:373-80.
36. Weinstock JV, Wahl SM. Mucosal immune response to parasitic infection. In: Ogra PL, Mestecky J, Lamm ME, et al., eds. Handbook of Mucosal Immunology. Vol. 1. San Diego: Academic Press, 1999:719-29.
37. Farah CS, Elahi S, Pang G, et al. T cells augment monocyte and neutrophil function in host resistance against oropharyngeal candidiasis. Infect Immun 2001;69:6110-8.
38. Smith PD, Wahl SM. Immunobiology of mucosal HIV infection. In: Ogra PL, Mestecky J, Lamm ME, et al., eds. Handbook of mucosal immunology. Vol. 1. San Diego: Academic Press, 1999:977-89.
39. Bellamy W, Wakabayashi H, Takase M, et al. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med Microbiol Immunol (Berl) 1993;182:97-105.
40. Challacombe SJ, Sweet SP. Salivary and mucosal immune responses to HIV and its co-pathogens. Oral Dis 1997;3(suppl 1):S79-84.
41. Challacombe SJ. Immunologic aspects of oral candidiasis. Oral Surg Oral Med Oral Pathol 1994;78:202-10.
42. Drobacheff C, Millon L, Monod M, et al. Increased serum and salivary immunoglobulins against Candida albicans in HIV-infected patients with oral candidiasis. Clin Chem Lab Med 2001;39:519-26.
43. Sugahara T, Murakami F, Yamada Y, et al. The mode of actions of lysozyme as an immunoglobulin production stimulating factor. Biochim Biophys Acta 2000;1475:27-34.
44. Akin DT, Lu MQ, Lu SJ, et al. Bactericidal activity of different forms of lactoferrin. Adv Exp Med Biol 1994;357:61-70.
45. Poles MA, Fuerst M, McGowan I, et al. HIV-related diarrhea is multifactorial and fat malabsorption is commonly present, independent of HAART. Am J Gastroenterol 2001;96:1831-7.
46. Janoff EN, Jackson S, Wahl SM, et al. Intestinal mucosal immunoglobulins during human immunodeficiency virus type 1 infection. J Infect Dis 1994;170:299-307.
47. Meillet D. Kapel N, Favennec L, et al. Intestinal humoral immunity and digestive opportunistic infections associated with AIDS. C R Seances Soc Biol Clin 1991;185:63-8.
48. Quesnel A, Moja P, Lucht F, et al. Is there IgA of gut mucosal origin in the serum of HIV-1-infected patients? Gut 1994;35:803-8.
49. Janoff EN, Scamurra RW, Sanneman TC, et al. Human immunodeficiency virus type 1 and mucosal humoral defense. J Infect Dis 1999;179(suppl 3):S475-9.